VX-765
- Generic Name
- VX-765
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 00OLE78529
- Background
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
- Indication
Investigated for use/treatment in inflammatory disorders (unspecified) and psoriasis and psoriatic disorders.
- Associated Conditions
- -
- Associated Therapies
- -
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 60
- Registration Number
- NCT01048255
- Locations
- 🇺🇸
Florida, Sarasota, Florida, United States
🇺🇸New York, New York, New York, United States
🇺🇸Missouri, Chesterfield, Missouri, United States
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-12-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 64
- Registration Number
- NCT00205465
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath